Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Colorectal Neoplasms

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 51 articles:
HTML format
Text format



Single Articles


    August 2017
  1. SCURR MJ, Pembroke T, Bloom A, Roberts DJ, et al
    Low-dose cyclophosphamide induces anti-tumor T-cell responses which associate with survival in metastatic colorectal cancer.
    Clin Cancer Res. 2017 Aug 29. pii: clincanres.0895.2017.
    PubMed     Text format     Abstract available


    June 2017
  2. YAO YM, Donoho GP, Iversen P, Zhang Y, et al
    Mouse PDX Trial Suggests Synergy of concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS mutations.
    Clin Cancer Res. 2017 Jun 13. pii: clincanres.3250.2016.
    PubMed     Text format     Abstract available


  3. PEKOW J, Meckel K, Dougherty U, Huang Y, et al
    miR-193a-3p is a key tumor suppressor in ulcerative colitis-associated colon cancer and promotes carcinogenesis through up-regulation of IL17RD.
    Clin Cancer Res. 2017 Jun 9. pii: clincanres.0171.2017.
    PubMed     Text format     Abstract available


  4. SCHOLER LV, Reinert T, Orntoft MW, Kassentoft CG, et al
    Clinical implications of monitoring circulating tumor DNA in patients with colorectal cancer.
    Clin Cancer Res. 2017 Jun 9. pii: clincanres.0510.2017.
    PubMed     Text format     Abstract available


  5. PRIEUR A, Cappellini M, Habif G, Lefranc MP, et al
    Targeting the Wnt pathway and cancer stem cells with anti-progastrin humanized antibodies: a major breakthrough for K-RAS mutated colorectal cancer treatment.
    Clin Cancer Res. 2017 Jun 9. pii: clincanres.0533.2017.
    PubMed     Text format     Abstract available


  6. GARLAN F, Laurent-Puig P, Sefrioui D, Siauve N, et al
    Early evaluation of circulating tumor DNA as marker of therapeutic efficacy in metastatic colorectal cancer patients (PLACOL study).
    Clin Cancer Res. 2017 Jun 2. pii: clincanres.3155.2016.
    PubMed     Text format     Abstract available


    May 2017
  7. STIEGELBAUER V, Vychytilova-Faltejskova P, Karbiener M, Pehserl AM, et al
    MicroRNA-196b-5p regulates colorectal cancer cell migration and metastases through interaction of HOXB7 and GALNT5.
    Clin Cancer Res. 2017 May 22. pii: clincanres.0023.2017.
    PubMed     Text format     Abstract available


  8. GOLDSTEIN JB, Wu W, Borras E, Masand G, et al
    Can Microsatellite Status of Colorectal Cancer be Reliably Assessed after Neoadjuvant Therapy?
    Clin Cancer Res. 2017 May 18. pii: clincanres.2994.2016.
    PubMed     Text format     Abstract available


    April 2017
  9. XU JM, Wang Y, Wang YL, Wang Y, et al
    PIK3CA mutations contribute to acquired cetuximab resistance in metastatic colorectal cancer patients.
    Clin Cancer Res. 2017 Apr 19. pii: clincanres.2738.2016.
    PubMed     Text format     Abstract available


  10. THIERRY AR, Pastor B, Jiang ZQ, Katsiampoura A, et al
    Circulating DNA demonstrates convergent evolution and common resistance mechanisms during treatment of colorectal cancer.
    Clin Cancer Res. 2017 Apr 11. pii: clincanres.0232.2017.
    PubMed     Text format     Abstract available


    March 2017
  11. CARBONE C, Piro G, Simionato F, Ligorio F, et al
    Homeobox B9 mediates resistance to anti-VEGF therapy in colorectal cancer patients.
    Clin Cancer Res. 2017 Mar 15. pii: clincanres.3153.2016.
    PubMed     Text format     Abstract available


  12. PARSEGHIAN C, Parikh NU, Wu JY, Jiang ZQ, et al
    Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer.
    Clin Cancer Res. 2017 Mar 9. pii: clincanres.3138.2016.
    PubMed     Text format     Abstract available


    February 2017
  13. WENG W, Wei Q, Toden S, Yoshida K, et al
    Circular RNA ciRS-7 - A promising prognostic biomarker and a potential therapeutic target in colorectal cancer.
    Clin Cancer Res. 2017 Feb 7. pii: clincanres.2541.2016.
    PubMed     Text format     Abstract available


    January 2017
  14. GOVERNA V, Trella E, Mele V, Tornillo L, et al
    The interplay between neutrophils and CD8+ T cells improves survival in human colorectal cancer.
    Clin Cancer Res. 2017 Jan 20. pii: clincanres.2047.2016.
    PubMed     Text format     Abstract available


    November 2016
  15. BLAJ C, Bringmann A, Schmidt EM, Urbischek M, et al
    ADNP is a therapeutically inducible repressor of WNT signaling in colorectal cancer.
    Clin Cancer Res. 2016 Nov 30. pii: clincanres.1604.2016.
    PubMed     Text format     Abstract available


  16. SUMMERS M, Smith CG, Maughan TS, Kaplan R, et al
    BRAF and NRAS locus specific variants have different outcomes on survival to colorectal cancer.
    Clin Cancer Res. 2016 Nov 4. pii: clincanres.1541.2016.
    PubMed     Text format     Abstract available


    October 2016
  17. PIETRANTONIO F, Vernieri C, Siravegna G, Mennitto A, et al
    Heterogeneity of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer.
    Clin Cancer Res. 2016 Oct 25. pii: clincanres.1863.2016.
    PubMed     Text format     Abstract available


  18. LIANG JQ, Chiu J, Chen Y, Huang Y, et al
    Fecal Bacteria Act as Novel Biomarkers for Non-Invasive Diagnosis of Colorectal Cancer.
    Clin Cancer Res. 2016 Oct 3. pii: clincanres.1599.2016.
    PubMed     Text format     Abstract available


  19. NEGRI FV, Boggiani D, Rimanti A, Musolino A, et al
    FCGR, Cetuximab, and Colorectal Cancer Survival-Letter.
    Clin Cancer Res. 2016;22:4958.
    PubMed     Text format    


    September 2016
  20. MA Y, Wang L, Neitzel LR, Loganathan S, et al
    The MAPK pathway regulates intrinsic resistance to BET inhibitors in colorectal cancer.
    Clin Cancer Res. 2016 Sep 27. pii: clincanres.0453.2016.
    PubMed     Text format     Abstract available


  21. PARK JH, Van Wyk HC, McMillan DC, Quinn JA, et al
    Signal transduction and activator of transcription-3 (STAT3) in patients with colorectal cancer: associations with the phenotypic features of the tumour and host.
    Clin Cancer Res. 2016 Sep 27. pii: clincanres.1416.2016.
    PubMed     Text format     Abstract available


  22. SALVUCCI M, Wurstle ML, Morgan C, Curry S, et al
    A stepwise integrated approach to personalized risk predictions in stage III colorectal cancer.
    Clin Cancer Res. 2016 Sep 20. pii: clincanres.1084.2016.
    PubMed     Text format     Abstract available


    August 2016
  23. SHIGEYASU K, Okugawa Y, Toden S, Boland CR, et al
    Exportin-5 functions as an oncogene and a potential therapeutic target in colorectal cancer.
    Clin Cancer Res. 2016 Aug 23. pii: clincanres.1023.2016.
    PubMed     Text format     Abstract available


  24. WEI TT, Lin YT, Tseng RY, Shun CT, et al
    Prevention of Colitis and Colitis-Associated Colorectal Cancer by a Novel Polypharmacological Histone Deacetylase Inhibitor.
    Clin Cancer Res. 2016;22:4158-69.
    PubMed     Text format     Abstract available


  25. TOFFOLI G, Sharma MR, Marangon E, Posocco B, et al
    Genotype-guided dosing study of FOLFIRI plus bevacizumab in metastatic colorectal cancer patients.
    Clin Cancer Res. 2016 Aug 9. pii: clincanres.1012.2016.
    PubMed     Text format     Abstract available


  26. YAMAMOTO T, Kawada K, Itatani Y, Inamoto S, et al
    Loss of SMAD4 Promotes Lung Metastasis of Colorectal Cancer by Accumulation of CCR1+ Tumor-associated Neutrophils through CCL15-CCR1 Axis.
    Clin Cancer Res. 2016 Aug 4. pii: clincanres.0520.2016.
    PubMed     Text format     Abstract available


  27. MUSTAFI R, Dougherty U, Mustafi D, Ayaloglu-Butun F, et al
    ADAM17 is a tumor promoter and therapeutic target in Western diet-associated colon cancer.
    Clin Cancer Res. 2016 Aug 3. pii: clincanres.3140.2016.
    PubMed     Text format     Abstract available



  28. Correction: MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
    Clin Cancer Res. 2016;22:3982.
    PubMed     Text format    


    July 2016
  29. TRINH A, Trumpi K, de Sousa E Melo F, Wang X, et al
    Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry.
    Clin Cancer Res. 2016 Jul 26. pii: clincanres.0680.2016.
    PubMed     Text format     Abstract available


  30. QIAN DC, Xiao X, Byun J, Suriawinata AA, et al
    PI3K/Akt/mTOR signaling and plasma membrane proteins are implicated in responsiveness to adjuvant dendritic cell vaccination for metastatic colorectal cancer.
    Clin Cancer Res. 2016 Jul 19. pii: clincanres.0623.2016.
    PubMed     Text format     Abstract available


  31. DE ROBERTIS M, Loiacono L, Fusilli C, Poeta LM, et al
    Dysregulation of EGFR pathway in EphA2 cell subpopulation significantly associates with poor prognosis in colorectal cancer.
    Clin Cancer Res. 2016 Jul 11. pii: clincanres.0709.2016.
    PubMed     Text format     Abstract available


  32. BENSON AB, Kiss I, Bridgewater J, Eskens FA, et al
    BATON-CRC: a phase II randomized trial comparing tivozanib plus mFOLFOX6 with bevacizumab plus mFOLFOX6 in stage IV metastatic colorectal cancer.
    Clin Cancer Res. 2016 Jul 11. pii: clincanres.3117.2016.
    PubMed     Text format     Abstract available


    June 2016
  33. BARRAS D, Missiaglia E, Wirapati P, Sieber OM, et al
    BRAF V600E mutant colorectal cancer subtypes based on gene expression.
    Clin Cancer Res. 2016 Jun 27. pii: clincanres.0140.2016.
    PubMed     Text format     Abstract available


  34. KUROIWA-TRZMIELINA J, Wang F, Rapkins RW, Ward RL, et al
    SNP rs16906252C>T is an expression and methylation quantitative trait locus associated with an increased risk of developing MGMT-methylated colorectal cancer.
    Clin Cancer Res. 2016 Jun 7. pii: clincanres.2765.2015.
    PubMed     Text format     Abstract available


    May 2016
  35. LIU G, Tu D, Lewis M, Cheng D, et al
    Fc-gamma Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer.
    Clin Cancer Res. 2016;22:2435-44.
    PubMed     Text format     Abstract available


  36. MUNAKATA K, Uemura M, Tanaka S, Kawai K, et al
    Cancer stem-like properties in colorectal cancer cells with low proteasome activity.
    Clin Cancer Res. 2016 May 10. pii: clincanres.1945.2015.
    PubMed     Text format     Abstract available


  37. WENG W, Okugawa Y, Toden S, Toiyama Y, et al
    FOXM1 and FOXQ1 are promising prognostic biomarkers and novel targets of tumor suppressive miR-342 in human colorectal cancer.
    Clin Cancer Res. 2016 May 9. pii: clincanres.0360.2016.
    PubMed     Text format     Abstract available


  38. DUNNE PD, McArt DG, Bradley CA, O'Reilly PG, et al
    Challenging the cancer molecular stratification dogma: Intratumoral heterogeneity undermines consensus molecular subtypes and potential diagnostic value in colorectal cancer.
    Clin Cancer Res. 2016 May 5. pii: clincanres.0032.2016.
    PubMed     Text format     Abstract available


    April 2016
  39. MEYN RE, Krishnan S, Skinner HD
    Everything Old Is New Again: Using Nelfinavir to Radiosensitize Rectal Cancer.
    Clin Cancer Res. 2016;22:1834-6.
    PubMed     Text format     Abstract available


  40. HILL EJ, Roberts C, Franklin JM, Enescu M, et al
    Clinical Trial of Oral Nelfinavir before and during Radiation Therapy for Advanced Rectal Cancer.
    Clin Cancer Res. 2016;22:1922-31.
    PubMed     Text format     Abstract available


  41. FERREIRO-NEIRA I, Torres NE, Liesenfeld LF, Chan CH, et al
    XPO1 Inhibition Enhances Radiation Response in Preclinical Models of Rectal Cancer.
    Clin Cancer Res. 2016;22:1663-73.
    PubMed     Text format     Abstract available


    February 2016
  42. DUDLEY JC, Lin MT, Le DT, Eshleman JR, et al
    Microsatellite Instability as a Biomarker for PD-1 Blockade.
    Clin Cancer Res. 2016;22:813-20.
    PubMed     Text format     Abstract available


  43. MEULENDIJKS D, Jacob W, Martinez-Garcia M, Taus A, et al
    First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors.
    Clin Cancer Res. 2016;22:877-85.
    PubMed     Text format     Abstract available


  44. PATNAIK A, Weiss GJ, Leonard JE, Rasco DW, et al
    Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors.
    Clin Cancer Res. 2016;22:827-36.
    PubMed     Text format     Abstract available


  45. MEULENDIJKS D, Lassen UN, Siu LL, Huitema AD, et al
    Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors.
    Clin Cancer Res. 2016;22:858-67.
    PubMed     Text format     Abstract available


  46. SCHELL MJ, Yang M, Missiaglia E, Delorenzi M, et al
    A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome.
    Clin Cancer Res. 2016;22:734-45.
    PubMed     Text format     Abstract available


  47. XU L, Ziegelbauer J, Wang R, Wu WW, et al
    Distinct Profiles for Mitochondrial t-RNAs and Small Nucleolar RNAs in Locally Invasive and Metastatic Colorectal Cancer.
    Clin Cancer Res. 2016;22:773-84.
    PubMed     Text format     Abstract available


  48. ARQUES O, Chicote I, Puig I, Tenbaum SP, et al
    Tankyrase Inhibition Blocks Wnt/beta-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
    Clin Cancer Res. 2016;22:644-56.
    PubMed     Text format     Abstract available


    January 2016
  49. ZIEMKE EK, Dosch JS, Maust JD, Shettigar A, et al
    Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6.
    Clin Cancer Res. 2016;22:405-14.
    PubMed     Text format     Abstract available


  50. TURKSMA AW, Coupe VM, Shamier MC, Lam KL, et al
    Extent and Location of Tumor-Infiltrating Lymphocytes in Microsatellite-Stable Colon Cancer Predict Outcome to Adjuvant Active Specific Immunotherapy.
    Clin Cancer Res. 2016;22:346-56.
    PubMed     Text format     Abstract available


  51. INAMOTO S, Itatani Y, Yamamoto T, Minamiguchi S, et al
    Loss of SMAD4 Promotes Colorectal Cancer Progression by Accumulation of Myeloid-Derived Suppressor Cells through the CCL15-CCR1 Chemokine Axis.
    Clin Cancer Res. 2016;22:492-501.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Colorectal Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: